Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, Atlanta, Georgia, USA.
Virology. 2010 Sep 15;405(1):165-75. doi: 10.1016/j.virol.2010.05.034. Epub 2010 Jun 26.
We generated influenza virus-like particles (VLPs) containing the wild type (WT) H5 hemagglutinin (HA) from A/Viet Nam/1203/04 virus or a mutant H5 HA with a deletion of the multibasic cleavage motif. VLPs containing mutant H5 HA were found to be as immunogenic as VLPs containing WT HA. A single intramuscular vaccination with either type of H5 VLPs provided complete protection against lethal challenge. In contrast, the recombinant H5 HA vaccine was less immunogenic and vaccination even with a 5 fold higher dose did not induce protective immunity. VLP vaccines were superior to the recombinant HA in inducing T helper type 1 immune responses, hemagglutination inhibition titers, and antibody secreting cells, which significantly contribute to inducing protective immunity after a single dose vaccination. This study provides insights into the potential mechanisms of improved immunogenicity by H5 VLP vaccines as an approach to improve the protective efficacy against potential pandemic viruses.
我们从 A/Viet Nam/1203/04 病毒或缺失多碱性裂解基序的突变型 H5 HA 中生成了含有野生型 (WT) H5 血凝素 (HA) 的流感病毒样颗粒 (VLPs)。含有突变型 H5 HA 的 VLPs 被发现与含有 WT HA 的 VLPs 具有同等的免疫原性。单次肌肉内接种任何一种 H5 VLPs 均可提供针对致死性挑战的完全保护。相比之下,重组 H5 HA 疫苗的免疫原性较低,即使接种 5 倍更高剂量也不能诱导保护性免疫。VLP 疫苗在诱导 T 辅助细胞 1 型免疫反应、血凝抑制滴度和抗体分泌细胞方面优于重组 HA,这对单次接种后诱导保护性免疫有重要贡献。本研究深入了解了 H5 VLP 疫苗提高免疫原性的潜在机制,作为提高针对潜在大流行病毒的保护效力的一种方法。